Alpha 2.0
Login Register
» Authors » Glen Clack

Glen Clack

Explore the profile of Glen Clack including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 23
Citations 1694
Followers 0
Related Specialties
Oncology
Biology
Molecular Biology
Top 10 Co-Authors
Matthew G Krebs
Richard Eastell
Rosemary A Hannon
Andrew Hughes
Caroline Dive
Richard D Baird
Malcolm Ranson
Paul Richards
R C Coombes
Jason Melear
Published In
Nat Commun
J Clin Oncol
J Bone Miner Res
J Thorac Oncol
J Invest Dermatol
Affiliations
Soon will be listed here.
Recent Articles
1.
Author Correction: Dose escalation and expansion cohorts in patients with advanced breast cancer in a Phase I study of the CDK7-inhibitor samuraciclib
Coombes R, Howell S, Lord S, Kenny L, Mansi J, Mitri Z, et al.
Nat Commun . 2025 Mar; 16(1):2242. PMID: 40050276
No abstract available.
2.
A Phase 1 Randomized, Placebo-Controlled Study Evaluating the Safety, Tolerability, and Pharmacokinetics of Enteric-Coated Stabilized Sulforaphane (SFX-01) in Male Participants
Clack G, Moore C, Ruston L, Wilson D, Koch A, Webb D, et al.
Adv Ther . 2024 Nov; 42(1):216-232. PMID: 39520658
Introduction: Sulforaphane (SFN) is a naturally occurring isothiocyanate associated with various health benefits, including reduced cancer risk, and has been extensively explored as a potential therapeutic. However, its inherent instability...
3.
Author Correction: Dose escalation and expansion cohorts in patients with advanced breast cancer in a Phase I study of the CDK7-inhibitor samuraciclib
Coombes R, Howell S, Lord S, Kenny L, Mansi J, Mitri Z, et al.
Nat Commun . 2023 Aug; 14(1):4741. PMID: 37550302
No abstract available.
4.
Dose escalation and expansion cohorts in patients with advanced breast cancer in a Phase I study of the CDK7-inhibitor samuraciclib
Coombes R, Howell S, Lord S, Kenny L, Mansi J, Mitri Z, et al.
Nat Commun . 2023 Jul; 14(1):4444. PMID: 37488191
Samuraciclib is a selective oral CDK7-inhibitor. A multi-modular, open-label Phase I study to evaluate safety and tolerability of samuraciclib in patients with advanced malignancies was designed (ClinicalTrials.gov: NCT03363893). Here we...
5.
A Phase I Trial of the Dual MET Kinase/OCT-2 Inhibitor OMO-1 in Metastatic Solid Malignancies Including MET Exon 14 Mutated Lung Cancer
Pruis M, Krebs M, Plummer R, de Vos F, Angevin E, Prenen H, et al.
Oncologist . 2023 Jun; 28(12):e1248-e1258. PMID: 37260332
Introduction: Targeted therapy in non-small cell lung cancer (NSCLC) patients with mesenchymal epithelial transition (MET) exon 14 skipping mutations (METex14) and MET amplifications has improved patients' outcomes. The development of...
6.
Ceralasertib (AZD6738), an Oral ATR Kinase Inhibitor, in Combination with Carboplatin in Patients with Advanced Solid Tumors: A Phase I Study
Yap T, Krebs M, Postel-Vinay S, El-Khouiery A, Soria J, Lopez J, et al.
Clin Cancer Res . 2021 Jul; 27(19):5213-5224. PMID: 34301752
Purpose: This study reports the safety, tolerability, MTD, recommended phase II dose (RP2D), pharmacokinetic/pharmacodynamic profile, and preliminary antitumor activity of ceralasertib combined with carboplatin in patients with advanced solid tumors....
7.
Continual reassessment method for dose escalation clinical trials in oncology: a comparison of prior skeleton approaches using AZD3514 data
James G, Symeonides S, Marshall J, Young J, Clack G
BMC Cancer . 2016 Sep; 16:703. PMID: 27581751
Background: The continual reassessment method (CRM) requires an underlying model of the dose-toxicity relationship ("prior skeleton") and there is limited guidance of what this should be when little is known...
8.
Clinical development of new drug-radiotherapy combinations
Sharma R, Plummer R, Stock J, Greenhalgh T, Ataman O, Kelly S, et al.
Nat Rev Clin Oncol . 2016 Jun; 13(10):627-42. PMID: 27245279
In countries with the best cancer outcomes, approximately 60% of patients receive radiotherapy as part of their treatment, which is one of the most cost-effective cancer treatments. Notably, around 40%...
9.
The value of integrating pre-clinical data to predict nausea and vomiting risk in humans as illustrated by AZD3514, a novel androgen receptor modulator
Grant C, Ewart L, Muthas D, Deavall D, Smith S, Clack G, et al.
Toxicol Appl Pharmacol . 2016 Feb; 296:10-8. PMID: 26876616
Nausea and vomiting are components of a complex mechanism that signals food avoidance and protection of the body against the absorption of ingested toxins. This response can also be triggered...
10.
Analytical validation of BRAF mutation testing from circulating free DNA using the amplification refractory mutation testing system
Aung K, Donald E, Ellison G, Bujac S, Fletcher L, Cantarini M, et al.
J Mol Diagn . 2014 Mar; 16(3):343-9. PMID: 24631158
BRAF mutation testing from circulating free DNA (cfDNA) using the amplification refractory mutation testing system (ARMS) holds potential as a surrogate for tumor mutation testing. Robust assay validation is needed...